Positive Ph3 Data for Aspergillosis Antifungal Treatment
Phase 3 trial results indicate a new antifungal medication olorofim is as effective as current standard treatments for invasive aspergillosis with fewer side effects.
Category: Pharmaceuticals
Pharmaceuticals
Latest
US Pharmaceuticals
Latest
Intl' Pharmaceuticals
Latest
Clinical Trials
Latest
New Avian Flu Vaccine Shows Promise in Protecting Humans, Cattle
Researchers developed an avian flu vaccine platform that generates immunity in the respiratory tract and bloodstream to combat H5N1.
Read More
Racial, Ethnic Disparities Persist in Asthma Inhaler Use
A study of over 1.1 million American adults with asthma found that Black, Hispanic, and Asian patients use ICS, LABA and LAMA inhalers less frequently than white patients.
Read More
FDA Approves Benralizumab for Hypereosinophilic Syndrome
Benralizumab (Fasenra) is now indicated to reduce the risk of flare ups for adult and pediatric patients with hypereosinophilic syndrome.
Read More
Enanta Pharma to Present Data for RSV, STAT6 Therapies at ATS 2026
Enanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read More
New Data on Inhaled Treprostinil for IPF
Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read More
Phase 1 Data Incoming for ALX1 iNO Therapy
Phase 1 results for the inhaled drug candidate ALX1 focus on safety and pharmacokinetics for the treatment of serious lung diseases.
Read More
Phase II Trial for Antiviral Nasal Spray Advances to Next Stage
The once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.
Read More
ALA Launches Study to Test Omalizumab for COPD Flare-ups
The COPD-OMA trial will examine if the asthma drug omalizumab (Xolair) benefits COPD patients with sensitivities to indoor allergens.
Read More
Tozorakimab Reduces COPD Flare-Ups in Ph3 Trial
The MIRANDA study found tozorakimab significantly lowered the rate of moderate-to-severe respiratory worsening in patients regardless of smoking history or specific white blood cell counts.
Read More
FDA Launches Real-Time Clinical Trial Initiative
The FDA is testing a new framework for monitoring safety signals as trials progress to reduce...
Read More
FDA Approves Breztri for Asthma Patients 12+
The single-inhaler therapy Breztri Aerosphere is now indicated for maintenance treatment in adults and pediatric patients who remain symptomatic on dual therapies.
Read More
Significant Gaps in Vaccine Uptake, Trust for US Adults
An NFID initiative provided evidence-based guidance on influenza, COVID-19, and RSV during the 2025-2026 season.
Read More
HCWs Report Fewer Side Effects from Protein-based COVID-19 Vaccine
A survey of frontline healthcare workers suggests a protein-based COVID-19 vaccine may cause fewer symptoms and less work disruption compared to mRNA options.
Read More
Asundexian Lowered Stroke Risk Without Increased Bleeding Complications
Bayer AG’s investigational drug asundexian reduced recurrent stroke risk by 26% in patients who recently experienced a stroke or temporary blockage of blood flow.
Read More
Naloxone May Not Fully Reverse Respiratory Depression From Synthetic Opioids
Standard doses of naloxone are often insufficient to restore normal breathing during opioid-induced respiratory depression (OIRD) after overdoses involving fentanyl and sufentanil.
Read More
FDA Approves IPF Generic Nintedanib
Dexcel Pharma USA will launch nintedanib capsules for patients with progressive lung disease following final regulatory approval.
Read More